News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Theravance Biopharma (TBPH) And Mylan (MYL) Report Additional Phase lll Data For Revefenacin (TD-4208) In Several Presentations At 2017 American Thoracic Society 5/24/2017
Boehringer Ingelheim Release: IPF Patients Treated With Ofev (Nintedanib) Versus Placebo Were Twice As Likely To Have Improved Or Stable Lung Function 5/24/2017
Sirtex Medical (SRX.AX) Release: Metastatic Colorectal Cancer Patients Treated First-Line With SIR-Spheres Y-90 Resin Microspheres More Likely To Become Candidates For Potentially Curative Liver Surgery, Resect Study Shows 5/24/2017
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Adults With Binge Eating Disorder At Annual American Psychiatric Association Meeting 5/24/2017
CEL-SCI (CVM) Craters Some More After the FDA Slaps Full Clinical Hold on Multikine Phase III Study 5/24/2017
Achaogen (AKAO) Release: Plazomicin Granted FDA Breakthrough Therapy Designation 5/24/2017
Amgen (AMGN) Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects 5/23/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/23/2017
AstraZeneca PLC (AZN) Release: Phase III ZONDA Trial For Benralizumab Shows Ability To Reduce Oral Steroid Use In Severe Asthma Patients 5/23/2017
Atox Bio's Reltecimod Passes Futility Analysis In Phase III ACCUTE Study; Trial Continues As Planned 5/23/2017
Sunovion Announces Utibron Neohaler (Indacaterol/Glycopyrrolate) Inhalation Powder Data Showing Lung Function And Health-Related Quality Of Life Improvement In Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease 5/23/2017
Sunovion Presents Phase III Data Showing Safety, Efficacy And Improvement In Quality Of Life Outcomes In Patients With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease Treated With SUN-101/Eflow (Glycopyrrolate) 5/23/2017
Boehringer Ingelheim Release: American Thoracic Society 2017 Spiriva Respimat Improves Breathing For People With Asthma Regardless Of BMI Or Allergic Status 5/23/2017
Onxeo Announces 10th Positive DSMB Recommendation To Continue Livatag Relive Phase III Trial In HCC 5/23/2017
ChemoCentryx (CCXI) Granted EU Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G) 5/23/2017
Cytori (CYTX) Logs Final 48 Week Patient Follow Up Visit In Scleroderma Trial 5/23/2017
TG Therapeutics (TGTX) Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial 5/23/2017
Novartis AG (NVS)' New Analyses Reinforce The Potential Of Ultibro Breezhaler For COPD Patients Historically Treated With Steroids 5/23/2017
5 Biotechs Releasing Highly-Anticipated Data at ASCO 5/22/2017
Meet The New CEO Of The Dutch Biotech Making A Cure For Blood Cancer 5/22/2017
Xynomic Pharma And UCSF Entered Strategic Partnership In Conducting A Phase II/III Trial Of Abexinostat Against Renal Cell Carcinoma 5/22/2017
Octapharma AG Underlines Strong Commitment To Haemophilia A Patients With The Publication Of New Clinical Data On PK-Guided Personalized Prophylaxis According To The Nupreviq Approach With Nuwiq 5/22/2017
Anika Therapeutics (ANIK) Announces Publication Of Phase III Data Demonstrating The Efficacy And Safety Of CINGAL For The Treatment Of Knee Pain Associated With Osteoarthritis 5/22/2017
Otsuka Pharma Announces Results Of Phase III Data On Tolvaptan 5/22/2017
Zogenix (ZGNX) Announces Presentation Of ZX008 Mechanism Of Action Data At Annual Meeting Of Society Of Biological Psychiatry 5/22/2017
Flexion (FLXN) To Present New Cost-Effectiveness Data On Zilretta (FX006) At The International Society For Pharmacoeconomics And Outcomes Research 22nd International Meeting 5/22/2017
Celgene (CELG) Notches Another Phase III Win for Potential MS Blockbuster Ozanimod 5/22/2017
Sunovion Announces Positive Results From Study Evaluating Latuda (Lurasidone HCL) In Children And Adolescents With Bipolar Depression At Annual American Psychiatric Association Meeting 5/22/2017
BerGenBio AS Announces Start Of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 In Combination With Current Therapies In Melanoma 5/22/2017
La Jolla Pharma (LJPC) Craters On Mixed Results Of Late-Stage Hypotension Study 5/22/2017
Nexstim Updates The Timeline For Its Supplementary E-FIT Phase III Trial In Stroke Rehabilitation 5/19/2017
Amgen (AMGN) Submits Biologics License Application To The FDA For Erenumab 5/19/2017
MT Pharma America Presents 12-Month RADICAVA (Edaravone) And Amyotrophic Lateral Sclerosis Data At The European Network For The Cure Of ALS (ENCALS) Annual Meeting 5/19/2017
Amicus (FOLD) Announces Planned Analysis Of Primary Endpoints In Phase III Epidermolysis Bullosa Study 5/19/2017
Shire (SHPG)'s $6.5 Billion Dyax (DYAX) Bet Pays Off as Lanadelumab Wows in Phase III Study 5/18/2017
Esperion (ESPR): Up, Up, And Away? 5/18/2017
Genmab A/S (GEN.CO) Announces Plans For New Studies Of Daratumumab 5/18/2017
TG Therapeutics (TGTX) Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The ASCO 5/18/2017
CytRx (CYTR) To Present Global Phase III Aldoxorubicin Clinical Data In Patients With Soft Tissue Sarcomas At The 2017 ASCO Annual Meeting 5/18/2017
AbbVie (ABBV) Presents Pivotal Phase III Data On Investigational Treatment Elagolix At The World Congress On Endometriosis 5/18/2017
Acorda (ACOR) To Present New INBRIJA (Levodopa Inhalation Powder) Phase III Data At Upcoming MDS Congress 5/18/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
Aurinia (AUPH) Doses First Patient In AURORA Phase III Clinical Trial Of Voclosporin In Lupus Nephritis 5/18/2017
Onconova (ONTX) To Present A Poster Session Relating To Intravenous Rigosertib At The 2017 ASCO Annual Meeting 5/18/2017
Recro Pharma (REPH) Presents Phase III Bunionectomy Clinical Data For IV Meloxicam At The American Pain Society 36th Annual Scientific Meeting 5/18/2017
Albireo (ALBO) Announces Plans For Phase III Clinical Program Of A4250 In Patients With PFIC 5/18/2017
Novartis AG (NVS) Data At ASCO, ICML And European Hematology Association Meetings Demonstrate Meaningful Advancements In Cancer Care 5/18/2017
Braeburn Pharma Keeps Up with Competitors with Long-Acting Risperidone for Schizophrenia 5/17/2017
Novo Nordisk A/S (NVO) Release: Early Response To Saxenda Resulted In Weight Maintenance And Additional Weight Loss Over 56 Week 5/17/2017
Promore Pharma Files Phase III Clinical Trial Application In India 5/17/2017
Safety Concerns Raised as Ionis Pharma (IONS)'s Inotersen Meets Both Primary Endpoints in Late-Stage Study 5/16/2017
Can-Fite BioPharma (CFBI) Files Clinical Trial Application In Canada For Piclidenoson Ahead Of Upcoming Acrobat Rheumatoid Arthritis Phase III Study 5/16/2017
Merck & Co. (MRK) To Present New Phase III Data On Investigational Ertugliflozin, Additional Analyses Of Studies Of JANUVIA (Sitagliptin), And Real-World Evidence Research At The 77th Scientific Sessions Of American Diabetes Association 5/16/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
Anthera Announces First Patient Screened In RESULT Pivotal Phase III Clinical Study Of Sollpura 5/16/2017
BrainStorm Cell Initiated Technology Transfer To City Of Hope For U.S. Production Of NurOwn For Phase lll ALS Study 5/16/2017
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study 5/15/2017
PhotoCure Release: Positive Data From Phase III US Blue Light Cystoscopy With Cysview Study Presented At American Urological Association 2017 Meeting In Boston 5/15/2017
AbbVie (ABBV) Release: IMBRUVICA (Ibrutinib) Pooled Outcomes Data From Three Phase III Studies Suggest Potential Clinical Efficacy In Patients With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 5/15/2017
Mologen (MOLGF.PK): Recruitment Goal Achieved For The Pivotal IMPALA Study With Lefitolimod In Colorectal Cancer Patients 5/15/2017
Biohaven (BHVN)'s Trigriluzole Receives Fast Track Designation From U.S. FDA 5/15/2017
PROCEPT BioRobotics' Aquablation Shows Superior Results Vs. TURP In WATER Blinded Randomized Trial For BPH 5/15/2017
Dendreon (DNDN) Announces Results Of New PROCEED Registry Analysis Showing Overall Survival Benefit With PROVENGE In Men With Metastatic Prostate Cancer 5/15/2017
First Patient Transfused In Cerus (CERS)’ Phase III RedeS Study Evaluating Safety And Efficacy Of The INTERCEPT Red Blood Cell System 5/15/2017
Sunovion To Present Clinical Efficacy, Safety And Health-Related Quality Of Life Outcomes Data From Its Respiratory Franchise At The American Thoracic Society 2017 International Conference 5/15/2017
Aurinia (AUPH) Reports First Quarter 2017 Financial Results, Announces Initiation Of Phase III Aurora Clinical Trial, And Provides Operational Highlights 5/15/2017
OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017 5/15/2017
Genentech (RHHBY)'s Top Cancer Prospect Flunks Phase III Test 5/12/2017
Ardelyx (ARDX) Reports Successful Phase III T3MPO-1 Trial Of Tenapanor In Patients With IBS-C 5/12/2017
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming Society Of Biological Psychiatry Annual Meeting 5/12/2017
PhotoCure: Phase III Study Investigating Blue Light Flexible Cystoscopy With Cysview In Surveillance Setting Meets Primary Endpoint 5/12/2017
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial 5/12/2017
Eli Lilly (LLY)'s Migraine Drug Hits Goals In Three Phase III Studies 5/12/2017
Orphazyme Completes Enrollment Of Patients For Phase III Clinical Trial In Niemann-Pick Type C Disease 5/11/2017
Why All Eyes Will be on Alnylam (ALNY) and Any Updates of Its APOLLO Phase III Trial This Friday 5/11/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Array BioPharma (ARRY) Shows Off Phase III Melanoma Data, Stock Jumps 5/11/2017
Genentech (RHHBY) To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 ASCO Annual Meeting 5/11/2017
Results Of The J-ALEX Study For Chugai Pharma's Alecensa Are Published In "The Lancet" Online 5/11/2017
Rhythm Receives Expanded FDA Breakthrough Therapy Designation For Setmelanotide For Rare Genetic Disorders Of Obesity 5/11/2017
Lexicon Pharma (LXRX) Reports Additional Positive Data From Pivotal InTandem1 Phase III Study For Sotagliflozin In Patients With Type 1 Diabetes 5/11/2017
Aimmune (AIMT) Enrolls First Patient In RAMSES (ARC007), A Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy 5/11/2017
Ocular Therapeutix (OCUL) Presented Phase III Data For DEXTENZA At Association for Research in Vision & Ophthalmology Annual Meeting 5/11/2017
Corium International, Inc. Reports Positive Preliminary Results In Alzheimer’s Clinical Study 5/11/2017
VBL Therapeutics (VBLX) Presents Data On VB-111 In Combination With Checkpoint Inhibitor At The 20th Annual ASGCT Meeting 5/11/2017
Kite Pharma (KITE) Stock Plunges After Report of Patient Death in CAR-T Clinical Trial 5/10/2017
AstraZeneca PLC (AZN)'s Asthma Drug Fails to Meet Primary Endpoint in Late-Stage Trial 5/10/2017
Synergy Pharma (SGYP) To Present Positive TRULANCE (Plecanatide) Phase III Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/10/2017
Actinium (ATNM.OB) Receives Clearance From Health Canada To Initiate Pivotal Phase III SIERRA Trial Of Iomab-B 5/10/2017
Evoke Pharma (EVOK) Presents Gimoti Efficacy And Safety Data From Phase III Trial As Late Breaker At Digestive Disease Week 2017 5/10/2017
Argos (ARGS) Provides Update On Its ADAPT Trial Following Meeting With FDA 5/10/2017
Cempra (CEMP) Presents Data On Ophthalmic Solithromycin At ARVO 5/10/2017
Proteon (PRTO) Receives FDA Breakthrough Therapy Designation For Vonapanitase 5/10/2017
3 Cancer Biotechs to Watch at ASCO 5/9/2017
Carmell Therapeutics Expands Manufacturing Capabilities To Support Phase III Clinical Trials 5/9/2017
Auris Med (EARS) Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study 5/9/2017
Recro Pharma (REPH) Announces Successful Top-Line Results From Phase III Safety Study Of IV Meloxica 5/9/2017
RegeneRx Biopharmaceuticals, Inc. (RGRX) JV Presents Results Of Phase IIb/III (ARISE-1) Dry Eye Trial At Association for Research in Vision & Ophthalmology 2017 5/9/2017
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Delayed Decline In Several Health-Related Quality Of Life Scales Compared To Temozolomide Alone For Newly Diagnosed Glioblastoma Patients 5/8/2017
Synergy Pharma (SGYP) To Present TRULANCE (Plecanatide) Phase III Data At Digestive Disease Week (DDW) For The Treatment Of Adults With Chronic Idiopathic Constipation (CIC) With Moderate To Very Severe Bloating 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Ocular Therapeutix (OCUL) Presents Additional Phase III Data And Patient Reported Outcomes Results For DEXTENZA At American Society of Cataract & Refractive Surgery Symposium 5/8/2017
Agile Therapeutics, Inc. Reports Additional Phase III SECURE Study Results Relating To Twirla At ACOG 2017 5/8/2017
Teva (TEVA), Active Biotech (BTPC) Suffer Another Setback After Laquinimod Flunks MS Study 5/8/2017
Faron Pharmaceuticals Ltd. Release: Update On Interest Phase III Study For Traumakine In Ards From IDMC 5/8/2017
Intra-Cellular Therapies (ITCI) Presents Data Supporting The Potential For Potent And Rapid Antidepressant Activity With Lumateperone 5/8/2017
Paratek Pharma (PRTK) Announces Completion Of Enrollment For Oral-Only Omadacycline Phase III Skin Study, Top-Line Data Expected In Mid-July 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
GlaxoSmithKline (GSK) Release: Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care 5/5/2017
European Society For Medical Oncology (ESMO) - Osimertinib Improves Symptoms In Advanced Lung Cancer Patients 5/5/2017
Rhythm Starts Phase III Clinical Trial Of Setmelanotide For Rare Genetic Disorder Of Obesity 5/4/2017
Pfizer (PFE) Release: Phase III OCTAVE Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal of Medicine 5/4/2017
Refocus Group (Formerly Presby) (RFCG) Concludes 12-Month Follow-Up For Phase III Clinical Trial On The Visability Micro-Insert System For Presbyopia; Readies For Pre-Market Approval Submission 5/4/2017
Allergan (AGN) R&D Chief: Company Forges Ahead With Migraine Treatments 5/3/2017
Soligenix (SNGX) Receives FDA Protocol Clearance Of Pivotal Phase III Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 5/3/2017
Proteon (PRTO) Announces Increase To Enrollment Of Ongoing Phase III PATENCY-2 Clinical Trial 5/3/2017
BioLineRx To Initiate Phase III Study With BL-8040 As Novel Stem Cell Mobilization Treatment Following Successful Meeting With FDA 5/3/2017
Foamix Pharma (FOMX) Announces Plans For Additional Phase III Trial For FMX101 In Moderate To Severe Acne 5/2/2017
Braeburn Pharma And Camurus Announce Positive Top-Line Results From Long-Term Phase III Safety Study Of CAM2038 5/2/2017
Otsuka Pharma And Lundbeck (LUN.CO) Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia 5/2/2017
Ocular Therapeutix (OCUL) To Present Data On Anterior And Posterior Segment Drug Product Candidates At Association for Research in Vision & Ophthalmology Annual Meeting 5/2/2017
Intra-Cellular Therapies (ITCI) Dropped To A New Low After the FDA Requests More Info On Schizophrenia Drug 5/2/2017
Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck (LUN.CO), Otsuka Pharma Investors Unsettled 5/2/2017
AMAG (AMAG) Announces Positive Topline Data From Phase III Feraheme (Ferumoxytol) Label Expansion Study 5/2/2017
Ablynx (ABLYF) Completes Patient Recruitment In Its Phase III Hercules Study Of Caplacizumab For The Treatment Of aTTP 5/2/2017
Ironwood (IRWD) To Present New Data For Linaclotide, Linaclotide Delayed Release And IW-1701 At Digestive Disease Week 2017 5/1/2017
Janssen R&D Submits Supplemental New Drug Application To U.S. FDA Based On EINSTEIN CHOICE Data, Which Showed Superiority With XARELTO (Rivaroxaban) Versus Aspirin In Reducing Risk Of Recurrent Venous Thromboembolism (VTE), With Low Rates Of Major Bleeding Across Groups 5/1/2017
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) For Squamous Cell Cancer Of The Head And Neck In Adults Progressing On Or After Platinum-Based Therapy 5/1/2017
Kala Pharma Announces Positive Results From Confirmatory Phase III Trial Of KPI-121 1% Following Cataract Surgery 5/1/2017
Aldeyra (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase III Clinical Trial 5/1/2017
Cytokinetics (CYTK) Announces Results From Dose Escalation Phase Of COSMIC-HF Presented At Heart Failure 2017 5/1/2017
Alkermes (ALKS) Announces Completion Of Patient Enrollment In Pivotal Antipsychotic Efficacy Study Of ALKS 3831 For Schizophrenia 5/1/2017
AEterna Zentaris (AEZS) Falling Hard On Failed Late-Stage Cancer Trial 5/1/2017
Key Capital Corporation Announces Groundbreaking Liver Cancer Immunotherapy Results 5/1/2017
Genmab A/S (GEN.CO) Announces New Phase III Combination Study Of Daratumumab In Multiple Myeloma 4/28/2017
EMD Serono Release: Investigational Cladribine Tablets Data Show Greater Treatment Effect In Relapsing MS Patients At A Higher Risk Of Disease Progression 4/28/2017
eMD Release: Investigational Cladribine Tablets Data Show Greater Treatment Effect In Relapsing MS Patients At A Higher Risk Of Disease Progression 4/28/2017
Medeor Receives FDA Clearance Of IND Application And Special Protocol Assessment For Pivotal Clinical Study Of MDR-101 4/28/2017
Teva Canada (TEVA) Announces Publication Of ARM-TD Study Results In Neurology For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 4/27/2017
Some Predict Biogen (BIIB)’s Alzheimer’s Drug Will Fail 4/27/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed 4/27/2017
Braeburn Pharma Achieves Primary Endpoint In Pivotal Phase II/III Study Of BB0817, Risperidone 6-Month Implant For Treatment Of Schizophrenia 4/27/2017
Proximagen Limited Release: Midazolam Nasal Spray (Usl261) Phase III Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 4/27/2017
Novan Presents Safety Data For SB204 Program 4/27/2017
Acceleron Pharma Provides Clinical Development Updates On Luspatercept Program 4/27/2017
Ultragenyx (RARE) Initiates Global Phase III Study Of UX007 In Glut1 DS Patients With Disabling Movement Disorders 4/27/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness 4/27/2017
Zogenix (ZGNX) Completes Enrollment In First ZX008 Phase III Clinical Trial In Dravet Syndrome 4/27/2017
Why This SoCal Pharma Could Be Your Best Bet on Alzheimer's 4/26/2017
ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial 4/26/2017
New Data At American Academy of Neurology Reinforce Clinical Benefit Of Genentech (RHHBY)'s OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis 4/26/2017
PhotoCure: Late-Breaking Plenary Presentation At The American Urological Association 2017 Annual Meeting On Blue Light Flexible Cystoscopy With Hexaminolevinulate Phase III Study 4/26/2017
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program 4/25/2017
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board 4/25/2017
Alzheon Scientists Discover Novel Therapeutic Mechanism Of Inhibition Of Formation Of Toxic Beta Amyloid Oligomers, Key Driver Of Alzheimer’s Disease Pathogenesis 4/25/2017
New Data Suggest Positive Effects Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) On Cortical Gray Matter Atrophy 4/25/2017
New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At American Academy of Neurology 4/25/2017
BeyondSpring Pharmaceuticals Enrolls First U.S. Patient In Phase II/III Clinical Trial Of Plinabulin For Neutropenia Prevention 4/25/2017
ObsEva (OBSV) Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids 4/25/2017
Shire (SHPG) Initiates Phase III Clinical Trial Program For SHP640 In Infectious Conjunctivitis For Adults And Children 4/25/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Eli Lilly (LLY) Finally Catches A Break With Encouraging Phase III Breast Cancer Data 4/24/2017
Pierre Fabre Publishes New Data On Dosing Errors With Generic Propranolol For The Treatment Of Infantile Hemangiomas 4/24/2017
Biogen (BIIB) Release: TECFIDERA And TYSABRI Data Demonstrate Improved Outcomes With Early MS Treatment 4/24/2017
Pfizer (PFE) Release: Pivotal Phase III Study Underscores Efficacy Of Zavicefta (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals 4/24/2017
American Regent, Inc. Announces Enrollment Of First Patient In Phase III Trial To Investigate Injectafer (Ferric Carboxymaltose) As Treatment For Heart Failure With Iron Deficiency 4/24/2017
Regeneron (REGN) And Sanofi (SNY) Receive Positive CHMP Opinion For Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Ocular Therapeutix (OCUL) To Present Additional Phase III Data And Patient Reported Outcomes Results For DEXTENZA At American Society of Cataract & Refractive Surgery Symposium 4/24/2017
Alder Biopharma Presents Additional Data From Eptinezumab Development Program At 69th Annual American Academy of Neurology Meeting 4/24/2017
Pfizer (PFE) Receives Positive CHMP Opinion For BESPONS (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia 4/24/2017
Adamas Pharma (ADMS) Presents ADS-5102 Pooled Phase III Data Confirming Statistically Significant Reduction In Levodopa-Induced Dyskinesia And OFF Time In People With Parkinson’s Disease 4/24/2017
Biogen (BIIB)'s Newly-Approved Spinraza Successful in Older Children With Spinal Muscular Atrophy 4/24/2017
Sirtex Medical (SRX.AX) Release: SIR-Spheres Y-90 Resin Microspheres Substantially Improves Quality Of Survival In Primary Liver Cancer, New Study Against Standard Treatment Shows 4/24/2017
Lipocine (LPCN) Completes Enrollment In The LPCN 1021 Fixed Dose Clinical Trials 4/24/2017
New Microbiology Data From Paratek Pharma (PRTK) Show Omadacycline Effective Against Most Common Skin Infections And Pathogens, Including MRSA 4/24/2017
Achaogen (AKAO) Unveils Data Highlighting The Effectiveness Of Plazomicin Against MDR Gram-Negative Bacteria At European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) 4/24/2017
New Health Economics Studies Highlight The Potential For Paratek Pharma (PRTK)’ Omadacycline To Provide Cost-Savings Compared To Standard Of Care For The Treatment Of Patients With Acute Bacterial Skin And Skin Structure Infections 4/24/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/24/2017
Auris Med (EARS) Reports Key Results From Keyzilen AMPACT2 Open-Label Extension Study 4/24/2017
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates In Challenging-To-Treat Genotype 3 Chronic HCV Patients 4/21/2017
Incyte (INCY)'s Immuno-Oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting 4/21/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/21/2017
Cempra (CEMP) Presents Data At ECCMID Highlighting Need For New CABP Therapies And Activity Of Solithromycin In Key Population Groups 4/21/2017
Basilea (BSLN.SW) Announces Agreement With FDA On Special Protocol Assessments For Antibiotic Ceftobiprole Phase III Clinical Studies In Bloodstream And Skin Infections 4/21/2017
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM 4/21/2017
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 4/21/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
Enanta Pharmaceuticals, Inc. Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 4/20/2017
AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis 4/20/2017
Gamida Cell Announces Publication Of Positive Clinical Outcomes From NiCord-Transplanted Patients In The Journal Of Biology Of Blood And Marrow Transplantation 4/20/2017
Lysogene Announces Selection Of MRI Interventions (MRIC)’ Smartflow Cannula For Phase II/III Clinical Study In MPS IIIA 4/20/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/20/2017
High Response And Remission Rates In Anti-Tnfa Naïve Patients Treated With Qu Biologics’ Novel Immune Therapy For Crohn’s Disease 4/20/2017
Octapharma USA Research Results Presented At HTRS Symposium Targeting Major Challenges Facing Hemophilia Patients 4/20/2017
AbbVie (ABBV)'s PARP Inhibitor Fails to Deliver in Two Late-Stage Studies 4/20/2017
Sunovion To Present Data On Aptiom (Eslicarbazepine Acetate) At American Academy of Neurology 2017 Annual Meeting 4/19/2017
Boehringer Ingelheim Phase III Study Now Enrolling Patients with Progressive Fibrosing Lung Diseases 4/19/2017
GNT Biotech and Medicals Corporation To Begin Phase III Clinical Trial In Taiwan Of Epigenetic Regulator Chidamide For Late-Stage Breast Cancer 4/19/2017